Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
comprised of over 30,000 employees and our vision is to attract, inspire, and develop outstanding people in medicine, sciences, and healthcare to become one of the world’s most distinguished academic health
-
medical and technological advancements since the opening of the U-M Medical School in 1850. Michigan Medicine is comprised of over 30,000 employees and our vision is to attract, inspire, and develop
-
medical and technological advancements since the opening of the U-M Medical School in 1850. Michigan Medicine is comprised of over 30,000 employees and our vision is to attract, inspire, and develop
-
technological advancements since the opening of the U-M Medical School in 1850. Michigan Medicine is comprised of over 30,000 employees and our vision is to attract, inspire, and develop outstanding people in
-
students; assist with audio/visual and computer technology and media in LSA classrooms and elsewhere. Respond to faculty, staff, and student needs, and collaborate with other Technology Services staff
-
since the opening of the U-M Medical School in 1850. Michigan Medicine is comprised of over 30,000 employees and our vision is to attract, inspire, and develop outstanding people in medicine, sciences
-
of the U-M Medical School in 1850. Michigan Medicine is comprised of over 26,000 employees and our vision is to attract, inspire, and develop outstanding people in medicine, sciences, and healthcare
-
of the U-M Medical School in 1850. Michigan Medicine is comprised of over 26,000 employees and our vision is to attract, inspire, and develop outstanding people in medicine, sciences, and healthcare
-
of the U-M Medical School in 1850. Michigan Medicine is comprised of over 26,000 employees and our vision is to attract, inspire, and develop outstanding people in medicine, sciences, and healthcare
-
Apply Now Job Summary The Nucleic Acid Therapeutics Core is a newly initiated program at the University of Michigan to design and synthesize nucleic acid therapeutic molecules for early-stage